Unit cost is the number that wins budget meetings. It's clean, it's comparable, and for years, it made offshore manufacturing in Asia look like an easy call.

But for medical device and pharma companies, the true cost of offshore manufacturing has a way of hiding—right up until something goes wrong. A delayed shipment. A failed audit. A recalled lot. By then, the savings on that original spreadsheet are long gone.

Total cost of ownership changes the conversation. When you account for logistics volatility, excess inventory carrying costs, tariffs, quality oversight travel, and the compounding risk of a 30-day supply chain, the offshore unit cost advantage doesn't just shrink—it often disappears entirely. In regulated industries where compliance failures are catastrophic and supply disruptions carry patient safety implications, the math has quietly tilted toward nearshore.

This post breaks down the full TCO framework: seven hidden cost categories that offshore quotes never show you, a side-by-side numerical comparison, and what it looks like when those factors are built into a real sourcing decision.